Renal Safety Across Tumour Types: ZOMETA® Safety & Tolerability
Home


About ZOMETA

ZOMETA Patient Case Studies

Zometa Dosing & Administration

ZOMETA Safety & Tolerability
Acute Phase Reactions
Renal Safety
Dental Health

ZOMETA Clinical News

ZOMETA For Your Patients

Professional Resource Center

ZOMETA Around the World
Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA Safety & Tolerability: Renal Safety


renal safety renal safety accross tumour types managing renal safety references

ZOMETA® has a well-characterised safety profile across multiple malignancies


ZOMETA renal safety profile in various malignancies



Breast cancer

ZOMETA did not cause grade 3/4* serum creatinine elevations in a randomised, placebo-controlled clinical trial in patients with breast cancer3

Prostate cancer

The incidence of grade 3* serum creatinine elevations in patients with prostate cancer was 3.3% for ZOMETA and 1.0% for placebo4
  • No grade 4* serum creatinine elevations were observed

Lung cancer

In patients with lung cancer or other solid tumours, the renal safety profile of ZOMETA has been shown to be similar to that of placebo (grade 3/4* serum creatinine elevations, 1.8% in both groups)5

Multiple myeloma

ZOMETA 4 mg every 3 to 4 weeks by 15-minute infusion demonstrated a similar renal safety profile to that of pamidronate 90 mg every 3 to 4 weeks by 90-minute infusion (grade 3/4* serum creatinine elevations, 0.4% vs 1.9%, respectively)6

  • ZOMETA 4 mg every 3 to 4 weeks has a well-characterised renal safety profile—even in patients who have had nephrectomies1,2
    • — For patients whose renal function is impaired due to renal cell carcinoma or other causes, the dose of ZOMETA can be adjusted to prevent safety issues1
*Grade 3 defined as >3x upper limit of normal (ULN); grade 4 defined as >6x ULN.